DarioHealth reveals 20-for-1 reverse stock split
Reverse Stock Split Announcement: DarioHealth will implement a reverse stock split of its common stock at a ratio of 20-for-1.
Effective Date: The reverse stock split is expected to take effect at market open on August 28.
Trading Information: Post-split, the company's common stock will continue trading on the Nasdaq Capital Market under the symbol "DRIO".
New CUSIP Number: After the split, the stock will have a new CUSIP Number, which is 23725P 308.
Trade with 70% Backtested Accuracy
Analyst Views on DRIO
About DRIO
About the author
DarioHealth Surpasses 100 Scientific Studies, Enhancing Digital Health Impact
- Research Milestone: DarioHealth announces it has surpassed 100 scientific studies, including peer-reviewed journal articles and conference abstracts, marking a significant achievement that enhances its reputation as a trusted partner for employers and health plans in digital health.
- Industry Leadership: Dario's extensive body of research positions it among the top tier in digital health, providing a substantial number of independent third-party studies that meet the rigorous demands of self-insured employers and health plans for measurable impact, thereby boosting its market competitiveness.
- Scientific Rigor: Chief Medical Officer Omar Manejwala emphasizes that crossing the 100-study milestone demonstrates Dario's outcomes are durable and repeatable, further solidifying its importance in value-based decision-making and driving broader adoption of digital health solutions.
- Future Outlook: As healthcare purchasers shift towards value-based decision-making, Dario's expanding portfolio of research is expected to support its continued growth in the digital health market, likely attracting more attention from employers and health plans.
DarioHealth Launches DarioIQ™ AI Platform for Initial Hypertension Users
- AI Platform Launch: DarioHealth introduces DarioIQ™, providing personalized guidance for hypertension users, leveraging 13 billion real-world data points, further solidifying the company's leadership in digital health.
- User Experience Optimization: By adopting a direct-to-consumer approach, DarioIQ™ pilots in a high-impact area, ensuring transparency and trust in user interactions, thereby laying the groundwork for future expansion.
- Technology Integration: DarioIQ™ combines three AI components—Advisor, Sentinel, and Strategist—to deliver real-time biometric interpretation and personalized interventions, enhancing user engagement and creating measurable value.
- Strategic Development: This launch marks a significant milestone in Dario's GenAI roadmap, aiming to drive market penetration in other chronic conditions such as diabetes and weight management through continuous AI capability expansion.
DarioHealth's Digital Nudges Significantly Lower Hypertension Outcomes
- Significant Clinical Impact: A study published by DarioHealth in JMIR Cardio shows that data-driven digital nudges lead to a statistically significant reduction of 2.09 mmHg in monthly average systolic blood pressure among high BP users three months post-intervention, compared to a 1.06 mmHg reduction in the control group, demonstrating effectiveness in improving cardiovascular health outcomes.
- Enhanced User Engagement: The research indicates that users with higher lifestyle activity levels achieved a greater systolic blood pressure reduction of 5.27 mmHg, underscoring the additive benefits of combining behavioral engagement with digital nudges, thereby enhancing DarioHealth's competitive position in the market.
- Cost Savings in Health: By improving hypertension control, DarioHealth's platform has the potential to reduce costs associated with cardiovascular complications, translating into measurable value for employers and healthcare systems while improving overall population health.
- Long-term Management Capability: The findings suggest that digital interventions are not merely momentary triggers but can support sustained hypertension management, further solidifying DarioHealth's leadership in the digital health space.
DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year
Study Findings: A peer-reviewed study by Sanofi and Symphony Health revealed that Dario's digital diabetes intervention platform resulted in 23% lower hospitalization rates and 26% lower healthcare charges compared to usual care for type 2 diabetes patients.
Engagement Impact: Increased engagement with the Dario platform was associated with fewer inpatient and emergency room events, highlighting the effectiveness of continuous digital health support.
Economic Validation: The study provided strong evidence that digital health interventions can significantly reduce healthcare costs and utilization, addressing key concerns of payers and employers regarding the financial impact of such solutions.
DarioHealth Overview: DarioHealth is a digital health company focused on chronic condition management, offering personalized interventions through a user-centric platform that aims to improve health outcomes and reduce costs for users and healthcare systems.
DarioHealth Corp. Reports Reduced Losses in Q3
Quarterly Loss: DarioHealth Corp. reported a loss of $10.47 million for the third quarter, improving from a loss of $12.33 million in the same period last year.
Earnings Per Share: The company's earnings per share (EPS) were -$2.96, compared to -$4.91 in the previous year.
Revenue Decline: Revenue for the quarter decreased by 32.5%, totaling $5.01 million, down from $7.42 million last year.
Financial Overview: The financial results indicate a significant reduction in losses year-over-year, despite a notable drop in revenue.
DarioHealth Unveils New Findings Showing Major Decrease in Medical Expenses for Employers Utilizing Its Digital Health Platform
Cost Savings from Digital Health: DarioHealth's research presented at ISPOR Europe 2025 shows significant medical cost reductions for employer members using its digital health platform, particularly among high-risk populations.
Integration of Technology and Coaching: The platform combines connected devices, AI-driven insights, and human coaching to improve health outcomes and reduce overall medical expenditures.
Real-World Evidence: This study marks Dario's first independent demonstration of its value using claims data, linking behavior change to measurable economic impact.
Focus on Chronic Conditions: DarioHealth's platform addresses multiple chronic conditions, aiming to disrupt traditional healthcare approaches and provide continuous, personalized care to improve user satisfaction and health management.
DarioHealth Surpasses 100 Scientific Studies, Enhancing Digital Health Impact
- Research Milestone: DarioHealth announces it has surpassed 100 scientific studies, including peer-reviewed journal articles and conference abstracts, marking a significant achievement that enhances its reputation as a trusted partner for employers and health plans in digital health.
- Industry Leadership: Dario's extensive body of research positions it among the top tier in digital health, providing a substantial number of independent third-party studies that meet the rigorous demands of self-insured employers and health plans for measurable impact, thereby boosting its market competitiveness.
- Scientific Rigor: Chief Medical Officer Omar Manejwala emphasizes that crossing the 100-study milestone demonstrates Dario's outcomes are durable and repeatable, further solidifying its importance in value-based decision-making and driving broader adoption of digital health solutions.
- Future Outlook: As healthcare purchasers shift towards value-based decision-making, Dario's expanding portfolio of research is expected to support its continued growth in the digital health market, likely attracting more attention from employers and health plans.
DarioHealth Launches DarioIQ™ AI Platform for Initial Hypertension Users
- AI Platform Launch: DarioHealth introduces DarioIQ™, providing personalized guidance for hypertension users, leveraging 13 billion real-world data points, further solidifying the company's leadership in digital health.
- User Experience Optimization: By adopting a direct-to-consumer approach, DarioIQ™ pilots in a high-impact area, ensuring transparency and trust in user interactions, thereby laying the groundwork for future expansion.
- Technology Integration: DarioIQ™ combines three AI components—Advisor, Sentinel, and Strategist—to deliver real-time biometric interpretation and personalized interventions, enhancing user engagement and creating measurable value.
- Strategic Development: This launch marks a significant milestone in Dario's GenAI roadmap, aiming to drive market penetration in other chronic conditions such as diabetes and weight management through continuous AI capability expansion.
DarioHealth's Digital Nudges Significantly Lower Hypertension Outcomes
- Significant Clinical Impact: A study published by DarioHealth in JMIR Cardio shows that data-driven digital nudges lead to a statistically significant reduction of 2.09 mmHg in monthly average systolic blood pressure among high BP users three months post-intervention, compared to a 1.06 mmHg reduction in the control group, demonstrating effectiveness in improving cardiovascular health outcomes.
- Enhanced User Engagement: The research indicates that users with higher lifestyle activity levels achieved a greater systolic blood pressure reduction of 5.27 mmHg, underscoring the additive benefits of combining behavioral engagement with digital nudges, thereby enhancing DarioHealth's competitive position in the market.
- Cost Savings in Health: By improving hypertension control, DarioHealth's platform has the potential to reduce costs associated with cardiovascular complications, translating into measurable value for employers and healthcare systems while improving overall population health.
- Long-term Management Capability: The findings suggest that digital interventions are not merely momentary triggers but can support sustained hypertension management, further solidifying DarioHealth's leadership in the digital health space.
DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year
Study Findings: A peer-reviewed study by Sanofi and Symphony Health revealed that Dario's digital diabetes intervention platform resulted in 23% lower hospitalization rates and 26% lower healthcare charges compared to usual care for type 2 diabetes patients.
Engagement Impact: Increased engagement with the Dario platform was associated with fewer inpatient and emergency room events, highlighting the effectiveness of continuous digital health support.
Economic Validation: The study provided strong evidence that digital health interventions can significantly reduce healthcare costs and utilization, addressing key concerns of payers and employers regarding the financial impact of such solutions.
DarioHealth Overview: DarioHealth is a digital health company focused on chronic condition management, offering personalized interventions through a user-centric platform that aims to improve health outcomes and reduce costs for users and healthcare systems.
DarioHealth Corp. Reports Reduced Losses in Q3
Quarterly Loss: DarioHealth Corp. reported a loss of $10.47 million for the third quarter, improving from a loss of $12.33 million in the same period last year.
Earnings Per Share: The company's earnings per share (EPS) were -$2.96, compared to -$4.91 in the previous year.
Revenue Decline: Revenue for the quarter decreased by 32.5%, totaling $5.01 million, down from $7.42 million last year.
Financial Overview: The financial results indicate a significant reduction in losses year-over-year, despite a notable drop in revenue.
DarioHealth Unveils New Findings Showing Major Decrease in Medical Expenses for Employers Utilizing Its Digital Health Platform
Cost Savings from Digital Health: DarioHealth's research presented at ISPOR Europe 2025 shows significant medical cost reductions for employer members using its digital health platform, particularly among high-risk populations.
Integration of Technology and Coaching: The platform combines connected devices, AI-driven insights, and human coaching to improve health outcomes and reduce overall medical expenditures.
Real-World Evidence: This study marks Dario's first independent demonstration of its value using claims data, linking behavior change to measurable economic impact.
Focus on Chronic Conditions: DarioHealth's platform addresses multiple chronic conditions, aiming to disrupt traditional healthcare approaches and provide continuous, personalized care to improve user satisfaction and health management.
